The study objective was to evaluate the safety and efficacy of below-the-ankle intervention in the office-based setting for treatment of chronic limb-threatening ischemia.
Two prespecified literature searches were conducted via Ovid utilizing the following databases: MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews (CDSR). We selected studies reporting amputation-free survival (AFS) in patients with non-revascularizable Rutherford category 5/6 CLI at a minimum follow-up of 6 months.
This randomized, controlled trial was designed to compare the rate of postangiographic contrast-induced nephropathy between the intra-arterial injections of carbon dioxide and the iodinated contrast agent.
Our study objective was to explore the potential cost-effectiveness of treatment with the LimFlow pDVA system (LimFlow SA) in the United States healthcare system.
We review here the mechanism of action of OA, supporting clinical study evidence, and corresponding economic analyses.
Despite medical advancements, PAD and CLI continue to increase globally. Treatment for PAD/CLI varies widely and patients with CTOs may be more challenging to treat, requiring specialized crossing techniques and modalities. The objective of this study was to determine the relationship between patients diagnosed with PAD/CLI, with CTOs, and subsequent long-term outcomes.